Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial​Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial 

 Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.  ​​Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.